Developer docs
API playgroundTry for free, no card

Search company profiles

Bimeda

Full company profile

uuid00092ht

Namestring
Bimeda
Legal namestring
Bimeda Holdings Limited
Websiteurl
bimeda.com
Company typeenum
Private
Founded yearint
1960
Descriptiontext

Bimeda Holdings Limited is an Irish-headquartered (Dublin) veterinary pharmaceutical company founded in 1960 and owned by the Tierney family since 1973. The company develops, manufactures, and distributes veterinary medicines, vaccines, nutritionals, and diagnostic services across livestock (cattle, poultry, sheep), companion animals (dogs, cats), equine, and aquaculture species, serving customers in over 80 countries through direct sales teams, exclusive distribution partnerships, and 10+ local country websites. Product lines span parasite management, infectious disease control, vaccines, reproductive health, joint health, sedatives, nutritional supplements, and aquaculture services through its AquaTactics division.

Bimeda operates nine manufacturing facilities across the United States (Le Sueur, San Angelo, Seattle), Canada (Cambridge), the United Kingdom (Denbigh), Ireland (Dublin), Brazil (Monte Mor), Argentina (Florida Oeste), and China (Shijiazhuang), plus eight R&D laboratories, with regulatory regimes covering FDA, USDA, EU EMA, MAPA, Senasa, and China Human Drug GMP. The company holds over 1,600 marketing authorisations globally and pioneered both the first intramammary teat sealant (1970s) and the world's only soluble glass multiple trace element bolus technology (Telsol). Diagnostic services are delivered through ISO 17025-accredited Iodolab (France), Bimeda Biologicals (San Angelo, Texas; St. Paul, Minnesota), and the FDA-inspected Rainbowlabs joint venture in China.

Revenue is generated predominantly through one-time product sales of pharmaceuticals and vaccines (pharmaceutical and nutritional products) plus ancillary revenue from diagnostic and aquaculture professional services. Pricing is not publicly disclosed; products are sold via direct enterprise sales to veterinarians and animal producers, via channel partners (e.g., Duggan Veterinary Supplies for UK/Ireland equine), and via regional e-commerce storefronts. Recent strategic activity (2022-2026) includes the Afrivet acquisition for African leadership, the €25M+ Shijiazhuang sterile injectable facility, USDA approval for autogenous fish vaccines in 2025, multi-phase Brazil expansion in 2025, and the April 2026 acquisition of Dechra's Pomona California manufacturing assets — all consistent with continued geographic and vertical expansion financed through family-owned capital rather than external investors.

Short descriptiontext

Bimeda is a privately-held, Ireland-headquartered veterinary pharmaceutical manufacturer founded in 1960 that develops and sells medicines, vaccines, nutritionals, and diagnostic services for livestock, companion animals, equine, and aquaculture species in over 80 countries through nine manufacturing facilities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices13 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary pharmaceuticals, animal health products, veterinary vaccines, livestock pharmaceuticals, aquaculture health services
Industry4 codes
1Veterinary Pharmaceutical Wholesalers & Distributors
CodeHLAMAIAAPrimaryYes
2Veterinary Vaccine & Biologics Distributors
CodeHLAMAIACPrimaryNo
3Veterinary Distributor Value-Added Services (3PL, Cold Chain, Returns)
CodeHLAMAIAGPrimaryNo
4Veterinary Vaccines (Biologics)
CodeHLAMAEALPrimaryNo
NAICS code1 code
  • Animal Food Manufacturing3111
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Biological Products, (No Disgnostic Substances)2836
Product category
Veterinary Pharmaceuticals
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Veterinary Pharmaceuticals Sales
TypeOne Time License
Description

Bimeda develops, manufactures, markets, and distributes veterinary medicines, vaccines, nutritionals and animal health products globally. Revenue is generated through direct product sales to veterinarians, animal producers, and through distribution partners.

bimeda.com
2Diagnostic Services
TypeProfessional Services
Description

Bimeda offers diagnostic and analytical services through diagnostic laboratories in France and the USA, providing testing and analysis services to pharmaceutical companies and animal health professionals.

bimeda.com
3Aquaculture Services
TypeProfessional Services
Description

Bimeda's aquaculture division AquaTactics provides fish health services including veterinary consultation, pathology, vaccination protocol design, and fish health products to aquaculture operations across the USA.

bimeda.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 18 records shown
1Bimectin
Description

Oral paste for equine/deworming

bimeda.com
+17 more records
Core offering1 text field

Bimeda develops, manufactures, markets, and distributes veterinary pharmaceuticals, vaccines, nutritional supplements, and animal health products across species including livestock, poultry, equine, companion animals, and aquaculture. The company operates 9 manufacturing facilities and 8 R&D facilities across 4 continents, and sells its products in over 80 countries through direct sales teams and distribution partners. It also offers diagnostic laboratory services and aquaculture-specific veterinary consultation and custom vaccine design through its AquaTactics division.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • ImmunIGY Bovine IgG test provides definitive direct results for calf IgG levels in 10 minutes, enabling early detection of Failure of Passive Transfer
+1 more record
Product overview1 text field

Bimeda Animal Health Ltd. is a global veterinary pharmaceutical and animal health company that develops, manufactures, markets, and distributes an extensive range of veterinary medicines, vaccines, nutritionals, and animal health products sold in over 80 countries worldwide. The company's product portfolio includes parasite management products (Bimectin Oral Paste, Embotape, Parvexon Plus), equine health products (Cronyxin Oral Paste, Gastrobim/Bimeprazol), anti-infectives (SpectoGard Sterile Solution), nutritional supplements (BOVitalize), diagnostic tools (ImmunIGY Bovine IgG), and aquaculture services (AquaTactics). Bimeda operates across eight focus areas: parasite management, nutrition, pain management, infectious disease management, vaccines and preventative health, reproductive health, joint health, sedatives, and aquaculture. The company offers products for livestock, poultry, horses, companion animals, and aquatic animals. Services include diagnostic laboratories in France and the USA (Iodolab, Bimeda Biologicals, Rainbowlabs), aquaculture services through AquaTactics, and sustainability initiatives.

Product and service18 records
1Bimectin Oral Paste
CategoryVeterinary pharmaceutical - equine parasiticide
Description

Oral paste deworming product for parasite management in horses.

2Embotape Oral Paste
CategoryVeterinary pharmaceutical - equine parasiticide
Description

Oral paste deworming product for parasite management in horses.

3Cronyxin Oral Paste
CategoryVeterinary pharmaceutical - equine
Description

Oral paste formulation for animal health management in horses.

4Gastrobim / Bimeprazol (Omeprazole Oral Paste)
CategoryVeterinary pharmaceutical - equine gastric health
Description

Omeprazole oral paste for gastric health management in horses. Distributed as Gastrobim in Ireland and Bimeprazol in the UK.

5SpectoGard (spectinomycin sulfate) Sterile Solution
CategoryVeterinary pharmaceutical - anti-infective (livestock)
Description

FDA-approved aminocyclitol antibiotic sterile injectable solution for cattle, for treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni. Bioequivalent to Adspec (Zoetis).

6BOVitalize
CategoryAnimal nutritional supplement
Description

Oral vitamin and mineral supplement for beef and dairy cows, bulls and ruminating calves. Contains selenium, copper, zinc, vitamin A and vitamin E. Administered as a single oral dose of 5 mL per 220 pound of body weight. Designed to support cattle productivity during stressful events.

7ImmunIGY Bovine IgG
CategoryVeterinary diagnostic test
Description

Novel blood test using lateral flow device that directly measures calf IgG levels in just 10 minutes, enabling early detection of Failure of Passive Transfer. Winner of the Royal Dairy Innovation Award 2024.

8Hemosilate
CategoryVeterinary pharmaceutical - companion animal haemostatic
Description

Bimeda product for use in dogs that reduces the severity and duration of bleeding by 50%, intended for emergency situations.

9Polyglycan
CategoryVeterinary pharmaceutical - joint health
Description

Veterinary product for joint health management in animals.

10Parvexon Plus Injection
CategoryVeterinary pharmaceutical - parasiticide (injection)
Description

Injection product for parasite management in animals.

11Coseicure
CategoryVeterinary pharmaceutical
Description

Animal health product in the Bimeda portfolio.

12Cidental
CategoryVeterinary pharmaceutical
Description

Animal health product in the Bimeda portfolio.

13Doracide
CategoryVeterinary pharmaceutical
Description

Animal health product in the Bimeda portfolio.

14Stimulator
CategoryVeterinary pharmaceutical
Description

Animal health product in the Bimeda portfolio.

15Macrosyn
CategoryVeterinary pharmaceutical
Description

Veterinary pharmaceutical product in the Bimeda portfolio.

16AquaTactics Autogenous Fish Vaccines
CategoryVeterinary vaccine - aquaculture
Description

USDA-approved custom autogenous fish vaccines produced at the Bimeda Biologicals facility in San Angelo, Texas, tailored to specific disease challenges in fish farms across all 50 U.S. states.

17Diagnostics Services
CategoryVeterinary diagnostic laboratory services
Description

Diagnostic and analytical laboratory services provided through Iodolab in France (NF EN ISO 17025:2017 accredited for trace elements, vitamins, and minerals testing), Bimeda Biologicals in San Angelo, Texas (microorganism analysis, serotyping, antibiotic sensitivity, virus/bacteria identification), Bimeda Biologicals in St. Paul, Minnesota (high throughput sequencing, Mycoplasma PCR, PRRSV PCR), and the Rainbowlabs joint venture in Shijiazhuang, China (FDA, Health Canada, ISO, CNAS accredited raw materials testing).

18AquaTactics Fish Health Services
CategoryAquaculture veterinary services
Description

Aquaculture division based in Seattle, Washington (USA) providing veterinary consultation, pathology services, fish health education, aqua-business coaching, regulatory approval consultation, and custom prescription vaccination design for fish farming operations.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierMinorTypeOthersAnnounced on2026-02-13
Description

Bimeda Ireland announced 2026 Corporate Partnership with National Society for the Prevention of Cruelty to Animals (NSPCA) in Ireland, strengthening long-standing commitment to supporting animal welfare and contributing positively to communities where they operate.

Strategic tierCoreTypeOthersAnnounced on2025-03-11
Description

AquaTactics, Bimeda's Washington-based aquaculture division, received USDA approval to enter the autogenous fish vaccine sector. Autogenous fish vaccine production and wet-lab safety testing takes place at Bimeda's vaccine facility Bimeda Biologicals in San Angelo, Texas, enabling production of custom vaccines tailored to specific disease challenges in fish farms across all 50 US states.

Strategic tierMinorTypeOthersAnnounced on2025-02-07
Description

Bimeda is a proud member of Access VetMed, the voice of Europe's generic veterinary medicines industry. Access VetMed published 2024 European Market Study on Generic and Value-Added Veterinary Medicines showing members hold 52% of all veterinary generic authorizations in Europe.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-12-01
Description

Bimeda Ireland and Bimeda UK announced exclusive equine product distribution partnership with Duggan Veterinary Supplies (DVS) effective January 1, 2025. Bimeda's equine-specific range including Bimectin Oral Paste, Embotape Oral Paste, Cronyxin Oral Paste, and Gastrobim/Bimeprazol oral paste will be distributed exclusively by DVS in UK and Ireland. All new Bimeda equine product introductions will also be distributed by DVS.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-29
Description

Bimeda partnered with Moredun Research Institute and University of Stirling's Institute of Aquaculture to develop a novel oral vaccine for salmon lice. Bimeda contributed £150k to the £1.5M project led by Dr Kim Thompson at Moredun. The project utilizes reverse vaccinology and AI via EpitoPredikt platform from EpitogenX to develop an oral vaccine for Atlantic salmon.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-29
Description

Collaboration on salmon louse vaccine development. Dr Sean Monaghan will conduct and run vaccine trials and assess molecular aspects of the parasite at infectious life stages that could be exploited for vaccination. Trials will take place at the University's Marine Environmental Research Laboratory (MERL).

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-29
Description

Collaboration partner in salmon louse vaccine development project with Industrial Award Partnership contribution from Bimeda.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-25
Description

Bimeda made substantial philanthropic donation to UCD Foundation to establish UCD Bimeda Herd Health Hub and AgTechUCD Innovation Centre at UCD Lyons Farm. The facility serves as a national facility for dairy herd health education, research, and consultancy, supporting state-of-the-art training for veterinary students. Funding also provided by Enterprise Ireland through Regional Enterprise Development Fund.

9Shijiazhuang Rainbowlabs Pharmaceutical Technology Co. Ltd
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-21
Description

Joint venture with Rainbowlabs providing high quality laboratory testing and services to pharmaceutical companies throughout the world. Rainbowlabs has received highest accreditation from U.S. FDA, Health Canada, ISO and CNAS. The facility provides complete release testing, R&D, and cGMP auditing capabilities.

bimeda.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries18 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bimeda

Veterinary Pharmaceuticalsbimeda.com

Bimeda is a privately-held, Ireland-headquartered veterinary pharmaceutical manufacturer founded in 1960 that develops and sells medicines, vaccines, nutritionals, and diagnostic services for livestock, companion animals, equine, and aquaculture species in over 80 countries through nine manufacturing facilities.

What Bimeda does

Bimeda Holdings Limited is an Irish-headquartered (Dublin) veterinary pharmaceutical company founded in 1960 and owned by the Tierney family since 1973. The company develops, manufactures, and distributes veterinary medicines, vaccines, nutritionals, and diagnostic services across livestock (cattle, poultry, sheep), companion animals (dogs, cats), equine, and aquaculture species, serving customers in over 80 countries through direct sales teams, exclusive distribution partnerships, and 10+ local country websites. Product lines span parasite management, infectious disease control, vaccines, reproductive health, joint health, sedatives, nutritional supplements, and aquaculture services through its AquaTactics division.

Bimeda operates nine manufacturing facilities across the United States (Le Sueur, San Angelo, Seattle), Canada (Cambridge), the United Kingdom (Denbigh), Ireland (Dublin), Brazil (Monte Mor), Argentina (Florida Oeste), and China (Shijiazhuang), plus eight R&D laboratories, with regulatory regimes covering FDA, USDA, EU EMA, MAPA, Senasa, and China Human Drug GMP. The company holds over 1,600 marketing authorisations globally and pioneered both the first intramammary teat sealant (1970s) and the world's only soluble glass multiple trace element bolus technology (Telsol). Diagnostic services are delivered through ISO 17025-accredited Iodolab (France), Bimeda Biologicals (San Angelo, Texas; St. Paul, Minnesota), and the FDA-inspected Rainbowlabs joint venture in China.

Revenue is generated predominantly through one-time product sales of pharmaceuticals and vaccines (pharmaceutical and nutritional products) plus ancillary revenue from diagnostic and aquaculture professional services. Pricing is not publicly disclosed; products are sold via direct enterprise sales to veterinarians and animal producers, via channel partners (e.g., Duggan Veterinary Supplies for UK/Ireland equine), and via regional e-commerce storefronts. Recent strategic activity (2022-2026) includes the Afrivet acquisition for African leadership, the €25M+ Shijiazhuang sterile injectable facility, USDA approval for autogenous fish vaccines in 2025, multi-phase Brazil expansion in 2025, and the April 2026 acquisition of Dechra's Pomona California manufacturing assets — all consistent with continued geographic and vertical expansion financed through family-owned capital rather than external investors.

Bimeda firmographics

Firmographics
Name
Bimeda
Legal name
Bimeda Holdings Limited
Website
https://bimeda.com
Company type
Private
Founded year
1960
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Bimeda is a privately-held, Ireland-headquartered veterinary pharmaceutical manufacturer founded in 1960 that develops and sells medicines, vaccines, nutritionals, and diagnostic services for livestock, companion animals, equine, and aquaculture species in over 80 countries through nine manufacturing facilities.
Ownership category
akta.pro rank

Bimeda industry classification

Industry
Product category
Veterinary Pharmaceuticals
NAICS
Animal Food Manufacturing (3111)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
Veterinary Pharmaceutical Wholesalers & Distributors (HLAMAIAA)
akta.pro secondary industries
Veterinary Vaccine & Biologics Distributors (HLAMAIAC), Veterinary Distributor Value-Added Services (3PL, Cold Chain, Returns) (HLAMAIAG), Veterinary Vaccines (Biologics) (HLAMAEAL)

Keywords

  • Veterinary pharmaceuticals
  • Animal health products
  • Veterinary vaccines
  • Livestock pharmaceuticals
  • Aquaculture health services

Where Bimeda is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices13 records

Markets served

Bimeda business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Veterinary Pharmaceuticals Sales: Bimeda develops, manufactures, markets, and distributes veterinary medicines, vaccines, nutritionals and animal health products globally. Revenue is generated through direct product sales to veterinarians, animal producers, and through distribution partners.
  2. Diagnostic Services: Bimeda offers diagnostic and analytical services through diagnostic laboratories in France and the USA, providing testing and analysis services to pharmaceutical companies and animal health professionals.
  3. Aquaculture Services: Bimeda's aquaculture division AquaTactics provides fish health services including veterinary consultation, pathology, vaccination protocol design, and fish health products to aquaculture operations across the USA.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Bimeda product offering

Product offering

Core offering

Bimeda develops, manufactures, markets, and distributes veterinary pharmaceuticals, vaccines, nutritional supplements, and animal health products across species including livestock, poultry, equine, companion animals, and aquaculture. The company operates 9 manufacturing facilities and 8 R&D facilities across 4 continents, and sells its products in over 80 countries through direct sales teams and distribution partners. It also offers diagnostic laboratory services and aquaculture-specific veterinary consultation and custom vaccine design through its AquaTactics division.

Product overview

Bimeda Animal Health Ltd. is a global veterinary pharmaceutical and animal health company that develops, manufactures, markets, and distributes an extensive range of veterinary medicines, vaccines, nutritionals, and animal health products sold in over 80 countries worldwide. The company's product portfolio includes parasite management products (Bimectin Oral Paste, Embotape, Parvexon Plus), equine health products (Cronyxin Oral Paste, Gastrobim/Bimeprazol), anti-infectives (SpectoGard Sterile Solution), nutritional supplements (BOVitalize), diagnostic tools (ImmunIGY Bovine IgG), and aquaculture services (AquaTactics). Bimeda operates across eight focus areas: parasite management, nutrition, pain management, infectious disease management, vaccines and preventative health, reproductive health, joint health, sedatives, and aquaculture. The company offers products for livestock, poultry, horses, companion animals, and aquatic animals. Services include diagnostic laboratories in France and the USA (Iodolab, Bimeda Biologicals, Rainbowlabs), aquaculture services through AquaTactics, and sustainability initiatives.

Differentiator

Problem solved

Functional benefit

Brands

  • Bimectin: Oral paste for equine/deworming
  • Macrosyn
  • Cidental
  • Coseicure
  • Doracide
  • Stimulator
  • Parvexon Plus Injection
  • Polyglycan
  • Cronyxin
  • BOVitalize
  • SpectoGard (spectinomycin sulfate)
  • ImmunIGY Bovine IgG
  • Gastrobim / Bimeprazol
  • AquaTactics
  • Iodolab
  • Rainbow Labs
  • Embotape
  • ImmunIGY

Products and services

  • Bimectin Oral Paste Oral paste deworming product for parasite management in horses.
  • Embotape Oral Paste Oral paste deworming product for parasite management in horses.
  • Cronyxin Oral Paste Oral paste formulation for animal health management in horses.
  • Gastrobim / Bimeprazol (Omeprazole Oral Paste) Omeprazole oral paste for gastric health management in horses. Distributed as Gastrobim in Ireland and Bimeprazol in the UK.
  • SpectoGard (spectinomycin sulfate) Sterile Solution FDA-approved aminocyclitol antibiotic sterile injectable solution for cattle, for treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni. Bioequivalent to Adspec (Zoetis).
  • BOVitalize Oral vitamin and mineral supplement for beef and dairy cows, bulls and ruminating calves. Contains selenium, copper, zinc, vitamin A and vitamin E. Administered as a single oral dose of 5 mL per 220 pound of body weight. Designed to support cattle productivity during stressful events.
  • ImmunIGY Bovine IgG Novel blood test using lateral flow device that directly measures calf IgG levels in just 10 minutes, enabling early detection of Failure of Passive Transfer. Winner of the Royal Dairy Innovation Award 2024.
  • Hemosilate Bimeda product for use in dogs that reduces the severity and duration of bleeding by 50%, intended for emergency situations.
  • Polyglycan Veterinary product for joint health management in animals.
  • Parvexon Plus Injection Injection product for parasite management in animals.
  • Coseicure Animal health product in the Bimeda portfolio.
  • Cidental Animal health product in the Bimeda portfolio.
  • Doracide Animal health product in the Bimeda portfolio.
  • Stimulator Animal health product in the Bimeda portfolio.
  • Macrosyn Veterinary pharmaceutical product in the Bimeda portfolio.
  • AquaTactics Autogenous Fish Vaccines USDA-approved custom autogenous fish vaccines produced at the Bimeda Biologicals facility in San Angelo, Texas, tailored to specific disease challenges in fish farms across all 50 U.S. states.
  • Diagnostics Services Diagnostic and analytical laboratory services provided through Iodolab in France (NF EN ISO 17025:2017 accredited for trace elements, vitamins, and minerals testing), Bimeda Biologicals in San Angelo, Texas (microorganism analysis, serotyping, antibiotic sensitivity, virus/bacteria identification), Bimeda Biologicals in St. Paul, Minnesota (high throughput sequencing, Mycoplasma PCR, PRRSV PCR), and the Rainbowlabs joint venture in Shijiazhuang, China (FDA, Health Canada, ISO, CNAS accredited raw materials testing).
  • AquaTactics Fish Health Services Aquaculture division based in Seattle, Washington (USA) providing veterinary consultation, pathology services, fish health education, aqua-business coaching, regulatory approval consultation, and custom prescription vaccination design for fish farming operations.

Quantifiable outcome

  • ImmunIGY Bovine IgG test provides definitive direct results for calf IgG levels in 10 minutes, enabling early detection of Failure of Passive Transfer
  • +1 more outcomes

Companies that use Bimeda

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Bimeda technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Bimeda partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered minor and core.

  • NSPCA (Ireland)minorOthers · 13 February 2026Bimeda Ireland announced 2026 Corporate Partnership with National Society for the Prevention of Cruelty to Animals (NSPCA) in Ireland, strengthening long-standing commitment to supporting animal welfare and contributing positively to communities where they operate.
  • USDAcoreOthers · 11 March 2025AquaTactics, Bimeda's Washington-based aquaculture division, received USDA approval to enter the autogenous fish vaccine sector. Autogenous fish vaccine production and wet-lab safety testing takes place at Bimeda's vaccine facility Bimeda Biologicals in San Angelo, Texas, enabling production of custom vaccines tailored to specific disease challenges in fish farms across all 50 US states.
  • Access VetMedminorOthers · 7 February 2025Bimeda is a proud member of Access VetMed, the voice of Europe's generic veterinary medicines industry. Access VetMed published 2024 European Market Study on Generic and Value-Added Veterinary Medicines showing members hold 52% of all veterinary generic authorizations in Europe.
  • Duggan Veterinary SuppliescoreChannel Partner/ Reseller/ Distributor · 1 December 2024Bimeda Ireland and Bimeda UK announced exclusive equine product distribution partnership with Duggan Veterinary Supplies (DVS) effective January 1, 2025. Bimeda's equine-specific range including Bimectin Oral Paste, Embotape Oral Paste, Cronyxin Oral Paste, and Gastrobim/Bimeprazol oral paste will be distributed exclusively by DVS in UK and Ireland. All new Bimeda equine product introductions will also be distributed by DVS.
  • Moredun Research InstitutecoreStrategic or Co-development Partner · 29 January 2024Bimeda partnered with Moredun Research Institute and University of Stirling's Institute of Aquaculture to develop a novel oral vaccine for salmon lice. Bimeda contributed £150k to the £1.5M project led by Dr Kim Thompson at Moredun. The project utilizes reverse vaccinology and AI via EpitoPredikt platform from EpitogenX to develop an oral vaccine for Atlantic salmon.
  • University of Stirling Institute of AquaculturecoreStrategic or Co-development Partner · 29 January 2024Collaboration on salmon louse vaccine development. Dr Sean Monaghan will conduct and run vaccine trials and assess molecular aspects of the parasite at infectious life stages that could be exploited for vaccination. Trials will take place at the University's Marine Environmental Research Laboratory (MERL).
  • Vertebrate Antibodies LtdminorStrategic or Co-development Partner · 29 January 2024Collaboration partner in salmon louse vaccine development project with Industrial Award Partnership contribution from Bimeda.
  • University College DublincoreStrategic or Co-development Partner · 25 October 2023Bimeda made substantial philanthropic donation to UCD Foundation to establish UCD Bimeda Herd Health Hub and AgTechUCD Innovation Centre at UCD Lyons Farm. The facility serves as a national facility for dairy herd health education, research, and consultancy, supporting state-of-the-art training for veterinary students. Funding also provided by Enterprise Ireland through Regional Enterprise Development Fund.
  • Shijiazhuang Rainbowlabs Pharmaceutical Technology Co. LtdcoreStrategic or Co-development Partner · 21 October 2022Joint venture with Rainbowlabs providing high quality laboratory testing and services to pharmaceutical companies throughout the world. Rainbowlabs has received highest accreditation from U.S. FDA, Health Canada, ISO and CNAS. The facility provides complete release testing, R&D, and cGMP auditing capabilities.

Scale indicators7 records

Recent moves10 records

Expansion highlights6 records

Bimeda competitors and assessment

Company assessment

Market position

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Bimeda compliance and trust

Trust signal

Compliance6 records

Bimeda financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bimeda leadership team

Management profile

Number of profiles

Profiles10 records

Bimeda subsidiaries and ownership

Company hierarchy

Subsidiaries18 records

Bimeda funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bimeda M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bimeda

What does Bimeda do?

Bimeda develops, manufactures, markets, and distributes veterinary pharmaceuticals, vaccines, nutritional supplements, and animal health products across species including livestock, poultry, equine, companion animals, and aquaculture. The company operates 9 manufacturing facilities and 8 R&D facilities across 4 continents, and sells its products in over 80 countries through direct sales teams and distribution partners. It also offers diagnostic laboratory services and aquaculture-specific veterinary consultation and custom vaccine design through its AquaTactics division.

Is Bimeda a public or private company?

Bimeda is a private company. It is classified as family owned and is currently operating.

When was Bimeda founded?

Bimeda was founded in 1960. It employs 501 to 1,000 people.

Where is Bimeda based?

Bimeda is headquartered in Dublin, Ireland, in the Europe region.

How does Bimeda make money?

Three revenue lines are on record. Veterinary Pharmaceuticals Sales are the primary driver. The others are diagnostic Services and aquaculture Services.

Does Bimeda have an API?

No public API is recorded for Bimeda.

What industry is Bimeda in?

Bimeda's product category is Veterinary Pharmaceuticals. Its primary akta.pro industry code is HLAMAIAA, Veterinary Pharmaceutical Wholesalers & Distributors, with a secondary code of HLAMAIAC, Veterinary Vaccine & Biologics Distributors. Its NAICS code is 3111 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAutogenous Vaccines Market to Reach US$ 451.5 Million by 2033; Expands Amid Rising Livestock Health Needs and Precision Disease ControlThe global autogenous vaccines market is valued at approximately US$ 312.4 million in 2026 and is projected to reach US$ 451.5 million by 2033, growing at a CAGR of 5.4%, driven by rising livestock disease burden, antimicrobial resistance concerns, and advances in rapid diagnostics. AquaTactics, Bimeda's Washington-based aquaculture division, received USDA approval in 2025 to enter the autogenous fish vaccine market, enabling production of farm-specific vaccines for fish health professionals and aquaculture facilities across all 50 US states. Bacterial strain vaccines dominate the market with nearly 78% revenue share, while Asia Pacific is identified as the fastest-growing region due to rapid livestock industrialization and aquaculture expansion.PR NewswireAutogenous Vaccines Market to Reach US$ 451.5 Million by 2033; Expands Amid Rising Livestock Health Needs and Precision Disease Control - Persistence Market ResearchThe global autogenous vaccines market is valued at approximately US$ 312.4 million in 2026 and is projected to reach US$ 451.5 million by 2033, reflecting a compound annual growth rate of 5.4% during the forecast period. Growth is driven by increasing livestock disease burden, rising antimicrobial resistance concerns, and advances in rapid diagnostics and vaccine production technologies that enable farm-specific immunization strategies. AquaTactics, Bimeda's Washington-based aquaculture division, received USDA approval in 2025 to enter the autogenous fish vaccine market, enabling production of custom vaccines tailored to specific disease challenges in fish farms across all 50 US states.openPR.comUnited States Autogenous Vaccines Market 2025: Industry Developments, Future Growth, Share & Industry Insights | Vaxxinova International BV, Bimeda Biologicals, HYGIEIA BIOLOGICALThe global autogenous vaccines market grew from $134.74 million in 2023 to $141.57 million in 2024, with a forecast to reach $228.66 million by 2033 at a 5.51% CAGR. Key players include Merck, Vaxxinova, and Bimeda, and recent news includes a new production facility in Germany and a USDA approval for aquaculture vaccines.PR NewswireGlobal Bovine Respiratory Disease Treatment Market 2022 to 2030: Players Include Bayer, Boehringer Ingelheim, Bimeda, Ceva and ElancoResearchAndMarkets.com published a market research report analyzing the global bovine respiratory disease treatment market from 2022 to 2030, covering market size, share, growth trends, and competitive landscape across treatment types (vaccines, antibiotics, immunomodulators), disease types (pneumonia, respiratory infections, diphtheria), and distribution channels. The report identifies North America as currently dominating the market while projecting Asia Pacific to exhibit the fastest growth rate during the forecast period. Key players profiled in the report include Bayer AG, Boehringer Ingelheim GmbH, Bimeda, Ceva, Elanco, Merck & Co., Inc., Merial, Virbac Group, Vetoquinol, and Zoetis Services LLC.